Review Article
Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review
Table 3
The blockade of immune checkpoints in prostate cancer.
| Drug | Agent description |
| Ipilimumab | The inhibition of CTLA-4 | Pembrolizumab (previously known as MK-3475 and lambrolizumab) | The inhibition of PD-1 | Pidilizumab | The inhibition of PD-1 |
|
|